Belite Bio (BLTE) Operating Income (2022 - 2026)

Belite Bio's Operating Income history runs 5 years deep, the most recent figure standing at -$32.7 million for Q1 2026.

• In Q1 2026, Operating Income rose 100.0% year-over-year to -$32.7 million; the TTM figure through Mar 2026 stood at -$40.6 billion (up 99.74% YoY), while the FY2025 annual figure was -$84.2 million, down 110.54% from the prior year.
• Operating Income was -$32.7 million for Q1 2026 at Belite Bio, down from -$28077.0 in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$2540.0 in Q3 2022 to a low of -$15517.0 billion in Q1 2025.
• Historically, Operating Income has averaged -$974.7 billion across 5 years, with a median of -$1.3 billion in 2022.
• The sharpest annual moves came in 2024 and 2026: Operating Income plunged 121028820.22% in 2024, then soared 100.0% in 2026.
• A 5-year view of Operating Income shows it stood at -$6.7 million in 2022, then declined by 3.48% to -$7.0 million in 2023, then jumped by 99.84% to -$11457.0 in 2024, then plunged by 145.06% to -$28077.0 in 2025, then slumped by 116308.45% to -$32.7 million in 2026.
• The last three Operating Income figures came in at -$32.7 million (Q1 2026), -$28077.0 (Q4 2025), and -$23.0 billion (Q3 2025), per Business Quant data.